TY - JOUR
T1 - The insula mediates the effects of glucocorticoids in anxiety
AU - Bahamonde, Tamara
AU - Quintana-Donoso, Daisy
AU - Linsambarth, Sergio
AU - Jerez-Baraona, Juan Manuel
AU - Peña, Francisca
AU - Tamburini, Giovanni
AU - Verdugo, Daniel Antonio
AU - Lemunao-Inostroza, Yordan
AU - Ogaz, Francisco
AU - Díaz-Galarce, Raúl
AU - Rojas, Sebastian
AU - Stehberg, Jimmy
N1 - Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/10/1
Y1 - 2023/10/1
N2 - Increased activity in the insula has been consistently reported to be associated with anxiety and anxiety-related disorders. However, little is known on how the insula regulates anxiety. The present study aims at determining the role of the insula on the effects of glucocorticoids in anxiety. A combination of pharmacological manipulations, including blockade of adrenal GC synthesis by metyrapone and intra-insular microinjections of corticosterone, corticosterone-BSA, mineralocorticoid receptor (MR) antagonist spironolactone and glucocorticoid receptor (GR) antagonist mifepristone, were used to assess the short-term (5 min) effects of intra-insular corticosterone in two anxiety-like behaviors in male Sprague-Dawley rats. The elevated plus maze (EPM) and Novelty Suppressed Feeding (hyponeophagia) were utilized. We found that corticosterone in the insula is sufficient to prevent the anxiolytic effects corticosterone synthesis blockade in anxiety, and that intra-insular corticosterone has anxiolytic or anxiogenic effects depending on the amount of corticosterone microinjected and the arousal associated to the test, without affecting the HPA axis. Glucocorticoid anxiolytic effects in the insula are mediated by MRs, while its anxiogenic effects are dependent on a mifepristone-sensitive membrane-bound mechanism. Anxiety appears to be modulated at the insula through a competition between fast MR-dependent anxiolytic and membrane-associated anxiogenic signaling pathways that orchestrate the behavioral response to stress and determines the resulting level of anxiety.
AB - Increased activity in the insula has been consistently reported to be associated with anxiety and anxiety-related disorders. However, little is known on how the insula regulates anxiety. The present study aims at determining the role of the insula on the effects of glucocorticoids in anxiety. A combination of pharmacological manipulations, including blockade of adrenal GC synthesis by metyrapone and intra-insular microinjections of corticosterone, corticosterone-BSA, mineralocorticoid receptor (MR) antagonist spironolactone and glucocorticoid receptor (GR) antagonist mifepristone, were used to assess the short-term (5 min) effects of intra-insular corticosterone in two anxiety-like behaviors in male Sprague-Dawley rats. The elevated plus maze (EPM) and Novelty Suppressed Feeding (hyponeophagia) were utilized. We found that corticosterone in the insula is sufficient to prevent the anxiolytic effects corticosterone synthesis blockade in anxiety, and that intra-insular corticosterone has anxiolytic or anxiogenic effects depending on the amount of corticosterone microinjected and the arousal associated to the test, without affecting the HPA axis. Glucocorticoid anxiolytic effects in the insula are mediated by MRs, while its anxiogenic effects are dependent on a mifepristone-sensitive membrane-bound mechanism. Anxiety appears to be modulated at the insula through a competition between fast MR-dependent anxiolytic and membrane-associated anxiogenic signaling pathways that orchestrate the behavioral response to stress and determines the resulting level of anxiety.
KW - Anxiety
KW - Corticosterone
KW - Elevated plus maze
KW - EPM
KW - Glucocorticoids
KW - GR, Glucocorticoid receptor
KW - Hyponeophagia
KW - Insula
KW - Insular cortex
KW - Membrane-associated glucocorticoids
KW - MR, Mineralocorticoid receptor
KW - Non-genomic glucocorticoid
KW - Novelty suppressed feeding test
UR - http://www.scopus.com/inward/record.url?scp=85161694446&partnerID=8YFLogxK
U2 - 10.1016/j.neuropharm.2023.109620
DO - 10.1016/j.neuropharm.2023.109620
M3 - Article
C2 - 37263575
AN - SCOPUS:85161694446
SN - 0028-3908
VL - 237
JO - Neuropharmacology
JF - Neuropharmacology
M1 - 109620
ER -